In conclusion, a cohort of 22 NSCLC patients with HER2 exon 20 insertion mutations was evaluated in a phase II study revealing an ORR of 38.1% and a median PFS of 2.8 months, highlighting the limited response duration associated with T-DM1 treatment [51]. Here, ERBB2 is linked to non-small cell lung carcinoma.